45
Participants
Start Date
August 4, 2024
Primary Completion Date
October 1, 2027
Study Completion Date
October 1, 2027
Envafolimab and recombinant human endostatin combined with chemoradiotherapy
Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
RECRUITING
Chongqing University Cancer Hospital, Chongqing
Fujian Cancer Hospital
OTHER_GOV
Sun Yat-sen University
OTHER
Chongqing University Cancer Hospital
OTHER